Oct. 27 at 12:24 PM
$INAB
Not only is Wall Street underappreciating
$INAB oncology pipeline, most investors are not even aware of their superior, in-hoise developed, autoimmune pipeline.
My guess is that larger biotechnology/pharmaceutical companies are very aware of whats going on at IN8bio. Wall Street will likely wake up to the stock after a headline (partnership) spikes the price per share to 5-10X from the current levels.
I've seen this movoe before. An example was
$FATE. It was dead money for a long time, then when the street woke up to the pipeline stock ripped from a few bucks per share to >
$100 per share in 2021.
There are too many others to list.
